{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:41:14Z","timestamp":1791877274711,"version":"4.3.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Swedish Cancer Society; the Swedish Research Council","award":["K2014\u201399X-22481\u201301-3"],"award-info":[{"award-number":["K2014\u201399X-22481\u201301-3"]}]},{"name":"Spanish Ministry of Economy and Competitiveness through the Carlos III Health Institute","award":["EC11\u2013423"],"award-info":[{"award-number":["EC11\u2013423"]}]},{"DOI":"10.13039\/501100018689","name":"Spanish Clinical Research Network","doi-asserted-by":"publisher","award":["SCReN-PT13\/0002\/0031"],"award-info":[{"award-number":["SCReN-PT13\/0002\/0031"]}],"id":[{"id":"10.13039\/501100018689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018689","name":"Spanish Clinical Research Network","doi-asserted-by":"publisher","award":["PT17\/0017\/0003"],"award-info":[{"award-number":["PT17\/0017\/0003"]}],"id":[{"id":"10.13039\/501100018689","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon 2020 research and innovation"},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The RAPIDO trial compared total neoadjuvant treatment (TNT) with preoperative chemoradiotherapy (CRT), both followed by total mesorectal excision, in patients with locally advanced rectal cancer (LARC). A higher locoregional recurrence (LRR) rate was observed after TNT. This study investigates factors contributing to the difference in LRR observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>Patients with high-risk LARC received TNT (5 \u00d7 5\u2005Gy followed by 6 \u00d7 CAPOX or 9 \u00d7 FOLFOX4) or CRT (25\u201328 \u00d7 1.8\u20132\u2005Gy with concurrent capecitabine). Patients with a local R0 or R1 resection were included in this study. Sphincter-preserving surgery encompassed (low) anterior resection and Hartmann\u2019s procedure. The influence of baseline, surgical and pathological factors on LRR was evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 920 randomized patients, 849 (430 versus 419 in the TNT and CRT arms) were eligible. The cumulative incidence of LRR at 8 years was 10.8% after TNT and 5.8% after CRT (HR 1.91). Following sphincter preserving surgery, 12.1% (TNT) and 4.8% (CRT) developed LRR (HR 2.60), compared to 8.5% versus 7.5%, respectively, after abdominoperineal resection. Distal resection margin rates (DRM) of 10 mm or less after sphincter-preserving surgery were similar in both arms (TNT 17.5% versus CRT 22.1%). However, a higher cumulative incidence of LRR was observed with a DRM of 10 mm or less after TNT (25.4% versus 1.8%; HR 15.51). Other factors were similar between treatment arms with respect to LRR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The difference in LRR between TNT and CRT mainly occurred in patients treated with sphincter-preserving surgery. Baseline information on the original tumour bed should be considered when determining the surgical approach after total neoadjuvant treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znaf190","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:43:08Z","timestamp":1759138988000},"source":"Crossref","is-referenced-by-count":11,"title":["Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment <i>versus<\/i> chemoradiotherapy in the RAPIDO trial"],"prefix":"10.1093","volume":"112","author":[{"given":"Ilaria","family":"Prata","sequence":"first","affiliation":[{"name":"GROW, School for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]},{"name":"Department of Surgery, Netherlands Cancer Institute , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Surgery, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max D","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Netherlands Cancer Institute , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris D","family":"Nagtegaal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Radboud University Medical Centre , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina G H","family":"Beets-Tan","sequence":"additional","affiliation":[{"name":"GROW, School for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]},{"name":"Department of Radiology, Netherlands Cancer Institute , Amsterdam ,","place":["The Netherlands"]},{"name":"Faculty of Health Sciences, University of Southern Denmark , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart K","family":"Blomqvist","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine\/Radiation Physics, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice M","family":"Couwenberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Netherlands Cancer Institute , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn","family":"van Etten","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Medical Centre Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A P","family":"Hospers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Centre Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elma","family":"Meershoek-Klein Kranenbarg","sequence":"additional","affiliation":[{"name":"Department of Surgery, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen C M J","family":"Peeters","sequence":"additional","affiliation":[{"name":"Department of Surgery, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-1422","authenticated-orcid":false,"given":"Hein","family":"Putter","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Sciences, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet G H","family":"Roodvoets","sequence":"additional","affiliation":[{"name":"Department of Surgery, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J H","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Department of Surgery, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-5887","authenticated-orcid":false,"given":"Per J","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Pelvic Cancer, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie A M","family":"Marijnen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Netherlands Cancer Institute , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Radiation Oncology, Leiden University Medical Centre , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2025092905430349600_znaf190-B1","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2007.15.3858","article-title":"Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer","volume":"26","author":"Braendengen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025092905430349600_znaf190-B2","doi-asserted-by":"crossref","DOI":"10.48101\/ujms.v129.10537","article-title":"Recent advances in rectal cancer treatment\u2014are we on the right track?","volume":"129","author":"Glimelius","year":"2024","journal-title":"Ups J Med Sci"},{"key":"2025092905430349600_znaf190-B3","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1002\/onco.13824","article-title":"Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"},{"key":"2025092905430349600_znaf190-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025092905430349600_znaf190-B5","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery\u2014a five-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"2025092905430349600_znaf190-B6","doi-asserted-by":"crossref","first-page":"102771","DOI":"10.1016\/j.eclinm.2024.102771","article-title":"Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US)","volume":"75","author":"Glimelius","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2025092905430349600_znaf190-B7","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.3390\/curroncol29050297","article-title":"Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis","volume":"29","author":"Liao","year":"2022","journal-title":"Curr Oncol"},{"key":"2025092905430349600_znaf190-B8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025092905430349600_znaf190-B9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.2002.07.010","article-title":"Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control","volume":"20","author":"Nagtegaal","year":"2002","journal-title":"J Clin Oncol"},{"key":"2025092905430349600_znaf190-B10","doi-asserted-by":"crossref","first-page":"114044","DOI":"10.1016\/j.ejca.2024.114044","article-title":"Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial","volume":"204","author":"Zwart","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025092905430349600_znaf190-B11","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/his.15027","article-title":"Relevance of shrinkage versus fragmented response patterns in rectal cancer","volume":"83","author":"Kus Ozturk","year":"2023","journal-title":"Histopathology"},{"key":"2025092905430349600_znaf190-B12","doi-asserted-by":"crossref","first-page":"101964","DOI":"10.1016\/j.ctrv.2020.101964","article-title":"How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement","volume":"84","author":"Nagtegaal","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2025092905430349600_znaf190-B13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/DCR.0b013e318269fdb3","article-title":"Tumor scatter after neoadjuvant therapy for rectal cancer: are we dealing with an invisible margin?","volume":"55","author":"Hayden","year":"2012","journal-title":"Dis Colon Rectum"},{"key":"2025092905430349600_znaf190-B14","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025092905430349600_znaf190-B15","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"2025092905430349600_znaf190-B16"},{"key":"2025092905430349600_znaf190-B17"},{"key":"2025092905430349600_znaf190-B18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1245\/s10434-011-2035-2","article-title":"Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review","volume":"19","author":"Bujko","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2025092905430349600_znaf190-B19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jamcollsurg.2011.07.020","article-title":"Pushing the envelope beyond a centimeter in rectal cancer: oncologic implications of close, but negative margins","volume":"213","author":"Fitzgerald","year":"2011","journal-title":"J Am Coll Surg"},{"key":"2025092905430349600_znaf190-B20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13193-022-01565-z","article-title":"The impact of narrow and infiltrated distal margin after proctectomy for rectal cancer on patients\u2019 outcomes: a systematic review and meta-analysis","volume":"13","author":"Metwally","year":"2022","journal-title":"Indian J Surg Oncol"},{"key":"2025092905430349600_znaf190-B21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bjs\/znac083","article-title":"Locally recurrent rectal cancer: oncological outcomes with different treatment strategies in two tertiary referral units","volume":"109","author":"Nordkamp","year":"2022","journal-title":"Br J Surg"},{"key":"2025092905430349600_znaf190-B22","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.05.245","volume-title":"Long-term Follow-up of a Nationwide Cohort of Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Treatment According to the LARCT-US Schedule and Risk Factors for Recurrence","author":"Imam","year":"2025"},{"key":"2025092905430349600_znaf190-B23","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/annonc\/mdz186","article-title":"Long-course preoperative chemoradiation versus 5 \u00d7 5\u2005Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study","volume":"30","author":"Cise\u0142","year":"2019","journal-title":"Ann Oncol"},{"key":"2025092905430349600_znaf190-B24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO-24-01676","article-title":"Neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: updated results of the FOWARC study after a median follow-up of 10 years","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025092905430349600_znaf190-B25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025092905430349600_znaf190-B26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"key":"2025092905430349600_znaf190-B27","doi-asserted-by":"crossref","first-page":"104483","DOI":"10.1016\/j.esmoop.2025.104483","article-title":"Chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: 5-year results of the CAO\/ARO\/AIO-12 trial\u2014a general pairwise comparison","volume":"10","author":"Diefenhardt","year":"2025","journal-title":"ESMO open"},{"key":"2025092905430349600_znaf190-B28","doi-asserted-by":"crossref","first-page":"S1211","DOI":"10.1016\/S0167-8140(25)01101-6","article-title":"2500 factors influencing locoregional recurrence rates in rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial","volume":"206","author":"Prata","year":"2025","journal-title":"Radiother Oncol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/112\/9\/znaf190\/64425854\/znaf190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/112\/9\/znaf190\/64425854\/znaf190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:43:12Z","timestamp":1759138992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znaf190\/8267712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znaf190","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9]]},"article-number":"znaf190"}}